Balyasny Asset Management
BEAM icon

Balyasny Asset Management’s Beam Therapeutics BEAM Stock Holding History

Balyasny Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43M Buy
+41,792
New +$1.26M ﹤0.01% 2000
2026
Q1 		– Sell
-32,711
Closed -$907K – 2902
2025
Q4 		$907K Buy
+32,711
New +$835K ﹤0.01% 2241
2025
Q2 		– Sell
-61,602
Closed -$1.2M – 2832
2025
Q1 		$1.2M Buy
+61,602
New +$1.61M ﹤0.01% 1918

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Balyasny Asset Management's BEAM Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 41,792 shares worth $1.43M. The stake represents ﹤0.01% of the portfolio and ranks #2000 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in BEAM as recently as Q4 2025.

Balyasny Asset Management first reported a position in BEAM in Q1 2025 and has held it in 3 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Balyasny Asset Management held 41,792 shares of Beam Therapeutics worth $1.43M as of Q2 2026.
  • Beam Therapeutics was a new Balyasny Asset Management position in Q2 2026.
  • Beam Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2000 holding.
  • Balyasny Asset Management first reported a position in Beam Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.